Faculty of Medicine
Permanent URI for this communityhttps://repository.ukim.mk/handle/20.500.12188/14
Browse
13 results
Search Results
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Rheumatoid arthritis and the proinflammatory cytokine IL-17(Pensoft Publishers, 2023-02-28); - Some of the metrics are blocked by yourconsent settings
Item type:Publication, C-REACTIVE PROTEIN IN RHEUMATOID ARTHRITIS TREATED WITH INTERLEUKIN-6 INHIBITOR(Macedonian Medical Association/De Gruyter, 2022); ; Arton JakupiRheumatoid arthritis (RA) is a chronic immune-me-diated systemic inflammatory disease characterized by chronic synovial inflammation and hyperplasia, which cause joint erosion and damage along with systemic manifestations. Proinflammatory pathways result in localized joint and systemic inflammation with cytokines, such as interleukin-6 (IL-6), tumour necrosis factor-α (TNF-α), interleukin 1β (IL-1β), as well as downstream signalling pathways. One function of IL-6 is to drive production of the acute-phase reactant C-reactive pro-tein (CRP) following an inflammatory event. C-reactive protein is not only a marker of inflamma-tion or infection, but it is also an immune regulator. C-reactive protein level is a component of several com-posite disease activity measures. Higher CRP levels are associated with greater RA disease activity, radiogra-phic progression and joint destruction. Yet, the usefulness of CRP testing as a routine measure of RA disease activity is not universal due to the sub-stantial proportion of treated patients who experience flares in their RA but still have normal CRP levels. There may be challenges in assessing remission with 28-joint Disease Activity Score -CRP (DAS28-CRP) when patients are treated with IL-6 inhibitors and other drugs that directly affect CRP levels because a reduction in CRP may not reflect disease activity decrease. The case that we present is a patient with seropositive RA in whom we tried all available RA treatment modalities including IL-6 inhibitor and two other biologicals, and despite the fact that we achieved low disease activity and sometimes even remission of the underlying disease, radiographic progression and sub-jective complaints of the patient continued. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Satisfaction Level of Rheumatoid Arthritis Patients Enrolled in the Treatment with Subcutaneous Tocilizumab. Journal of Autoimmune Diseases and Rheumatology(Karachi: Synergy Publishers, 2020); - Some of the metrics are blocked by yourconsent settings
Item type:Publication, SECONDARY SJOGREN’S SYNDROME IN PATIENTS WITH RHEUMATOID ARTHRITIS(Институт за јавно здравје на Република Северна Македонија, 2022); ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, DIAGNOSTIC UTILITY OF ANTI-CCP ASSAY IN PATIENTS WITH RHEUMATOID ARTHRITIS(Macedonian Association of Anatomists and Morphologists, 2021-12); ; ; Krstevska Balkanov, SvetlanaIntroduction: The purpose of this research was to compare the diagnostic values of laboratory variables, to present quantitative evaluations of the diagnostic test with reference value for anti-cyclic citrullinated peptide (anti-CCP2) antibodies, rheumatoid factor (RF), Creactive protein (CRP), and DAS 28 index in early diagnosis of untreated rheumatoid arthritis (RA). Material and methods: Using the ELISA method of DIA-STAT™ Anti CCP (Axis-Shield Diagnostics), sera of 70 participants were examined (35 untreated patients with RA and 35 subjects from the healthy control group). RF and CRP were determined with the agglutination test (Latex test) in the same participants. At the same time, we determined the sensitivity, specificity, predictive value for positive and negative test and accuracy. Results: Presence of anti-CCP 2 antibodies was 65.71%, 23/35 patients, while RF was present in 17/35 (48.57%). Twelve patients were anti-CCP2 and RF positive, 11 were antiCCP2 positive, but RF negative. Five patients were anti-CCP2 negative and RF positive. In the healthy control group, one patient was anti-CCP2 positive, while 2 patients were RF positive. Conclusion: Anti-CCP2 antibodies have higher sensitivity and specificity than RF in early RA - Some of the metrics are blocked by yourconsent settings
Item type:Publication, RADIOGRAPHIC ASSESSMENT OF JOINT DAMAGE IN EARLY RHEUMATOID ARTHRITIS PATIENTS TREATED WITH METHOTREXATE(Macedonian Association of Anatomists, 2021-03); ; ; In rheumatoid arthritis (RA), progression of the radiographic damage of hand and feet joints is a significant and objective variable for evaluation of disease activity as well as measurement of treatment outcome. The aim of this study was to evaluate the RA activity with radiographic evaluation of hand joints in patients with early RA treated with Methotrexate by using acute phase reactants, as rheumathoid factor (RF), C-reactive protein (CRP) and DAS28 index of disease activity. We tested 70 participants (35 control patients, 35 untreated RA patients). Patients were treated with Methotrexate at an average dose of 10 mg once weekly. For clinical evaluation of disease activity radiographic index (RI), sedimentation, CRP and RF in certain time intervals (0-time, after 6, 9 and 12 months) were analyzed in every patient. RI showed an increased radiographic progression of hand joint damage in time intervals between 0-time and 9 months (p=0,0167) and between 0-time and 12 months (p=0.0089). The statistical analysis showed statistically significant differences among mean values of ESR in the four-time intervals (p=0.00002). - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Medically treated emphysematous gastritis in a patient with rheumatoid arthritis: report of case(DergiPark Akademik, 2021-12-14); ; Tuba SaydamEmphysematous gastritis is rare infection of the gastric wall associated with high mortality. Damage of the gastric mucosal barrier and bacterial translocation can lead to emphysematous gastritis. Non-steroidal anti-inflammatory drugs use is one of the etiological factors. Due to the high mortality rates, early diagnosis and treatment is important. Patients are presenting to emergency departments generally with non-specific acute abdominal signs. We present a case of an 82 years old patient with rheumatoid arthritis treated with non-steroidal anti-inflammatory drug that presented to the emergency department with diffuse abdominal pain, nausea and vomiting. After establishing the diagnosis, conservative treatment was conducted with success. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, ML28133 -A MULTICENTER, OPEN-LABEL, LONG-TERM EXTENSION STUDY OF WA 19926 TO DESCRIBE SAFETY DURING TREATMENT WITH TOCILIZUMAB IN PATIENTS WITH EARLY, MODERATE TO SEVERE RHEUMATOID ARTHRITIS(Македонско лекарско друштво = Macedonian Medical Association, 2017); - Some of the metrics are blocked by yourconsent settings
Item type:Publication, ACR20 AND ACR50 CRITERIA FOR THE ASSESSMENT OF TREATMENT RESPONSE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH METHOTREXATE(Македонско лекарско друштво = Macedonian Medical Association, 2019); ; Introduction. Multiple comparative studies have assessed the therapeutic effect of methotrexate (MTX) and have shown that it is the leading disease modifying anti-rheumatic drug (DMARD) in the treatment of rheumatoid arthritis (RA). A quantitative appraisal of the therapeutic response of this drug in a set period of time is of great importance. Aim. To make an assessment of the therapeutic response to MTX, by using the American College of Rheumatologists (ACR), ACR20 and ACR50 criteria, for a fixed time period, in patients with rheumatoid arthritis and long disease evolution. Methods. In this prospective study we examined 60 patients with RA, of which 30 with disease evolution less than one year (average disease duration 5.1+/-2.8 months, 2-11 months), and 30 with disease duration over 5 years (average disease duration 7.9+/-1.8 years, 5-12 years). They were treated with an average dose of 7.5mg MTX weekly and non-steroid anti-inflammatory drugs (NSAID) as needed. In patients with early RA, MTX was used for the first time. At baseline all patients had active disease. ACR20 and ACR50 were assessed in all patients for the duration of the study. Results. After one year 26 (86.7%) of patients with early RA had satisfied ACR20 criteria compared to 18 (62.1%) of the patients with late arthritis. After two years this changed to 25 (83.3%) vs. 20 (69%) patients, respectively. ACR50 criteria after one year of treatment were satisfied in 12 (40%) patients with early arthritis and 8 (27.6%) with late arthritis, over 5 years of disease evolution. After two years data showed 21 (70%) vs. 10 (34.5%) patients, respectively. Conclusion. Early application of MTX in patients with arthritis allows for significantly better improvement in patients with RA compared to the use of the same treatment in those with a longer evolution of the disease. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, SYMMETRIC DIMETHYL ARGININE AND N-ACETYL-Β-DGLUCOSAMINIDASE LYSOZIMURIA OF PROXIMAL RENAL TUBULES AS A TARGET FOR NEPHROTOXICITY IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH DISEASE MODIFYING ANTIRHEUMATIC DRUGS(2013);